This company develops ultra-sensitive multi-omics biomarker detection technology for healthcare applications. Their pipeline includes urine-based tests for bladder cancer monitoring and early detection, as well as a liquid biopsy for advanced prostate cancer. The platform offers attomolar sensitivity for non-invasive clinical decision support in oncology.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for bladder cancer monitoring rely on invasive cystoscopies, which are costly and uncomfortable for patients. Existing non-invasive assays often lack the sensitivity needed for early and accurate detection of recurrence. This can lead to delayed diagnoses and increased healthcare costs.
Solution
Early is Good provides an ultra-sensitive multi-omics platform for non-invasive cancer diagnostics, initially focused on bladder cancer monitoring and early detection. Their Multi-Omics Integration Platform (MIP) simultaneously analyzes DNA, RNA, proteins, and small molecules from urine samples, eliminating the need for extraction or amplification. The platform achieves attomolar sensitivity, enabling earlier and more accurate detection of cancer biomarkers compared to traditional methods. The streamlined workflow allows for rapid analysis with results available in under 4 hours using a standard plate reader. This approach reduces the need for invasive procedures, improves patient comfort, and facilitates timely intervention.
Target Audience
The primary target audience includes urologists, oncologists, and clinical laboratories involved in bladder cancer monitoring and early detection, as well as pharmaceutical companies and research institutions interested in biomarker discovery and assay development.
Features
- Simultaneous detection of DNAs, RNAs, proteins, and small molecules in a single assay
- Attomolar (10^-18) sensitivity for early detection of cancer biomarkers
- Non-invasive urine and blood sample types
- Assay time of less than 4 hours
- Simplified workflow with no extraction or amplification required
- Quantifiable and unbiased analysis readout from a basic plate reader
- Reproducible results with CV (coefficient of variation) less than 3%
- BCDx Monitoring product for active surveillance of bladder cancer recurrence
- BCDx Detect product for early bladder cancer detection